Truscreen Group Ltd. · NZX:TRU
Truscreen — Shareholder Meeting (September 2021)
18 slides from Truscreen's shareholder meeting presentation, Sep 7, 2021
Slide 1: Annual Shareholders Meeting
Annual Shareholders Meeting TruScreen Group Limited 7 September 2021 ASX | NZX: TRU truscreen
Slide 2: TruScreen Cervical Cancer Screening Device
truscreen A-enobiea TruScreen’s is a Cervical Cancer Screening Device which offers the latest technology in cervical screening, providing real-time detection of pre-cancerous and cancerous cervical cells to help improve the health and well-being of women around the world. TruScreen is': - Non-invasi
Slide 3: Traditional screening methods have not been successful in LMICs
Traditional methods to screen women for cervical cancer have not been successful in LMCls*. Innovative screening models are required if LMIC’s are to meet WHO's three targets by 2030. 90% coverage of HPV vaccination for girls <15 years old of women screened with high performance tests by the age of
Slide 4: FY2021 Results
FY2021 Results April 2020 — March 2021
Slide 5: FY2021 Highlights
FY2021 Highlights 27 truscreen eMarket development in Central & Eastern Europe (CEE) eSuccessfully dual listed on ASX eCommenced first evaluation in the Middle East eCompleted initial phase of establishing local assembly in China eAchieved 156 commercial installations (+100% YoY)
Slide 6: FY2021 Key Financials
KEY FINANCI. FY19 Actual FY20 Actual FY21Actual FY21/FY20 NZD (m) FY?0?1 Sales 19 13 W -12% : : Total Revenue 31 25 19 -23% Financials cos ney R&D 17 i 13 EBITDA (2.8) (2.1) (2.8) -33% Net Assets 1.3 7.2 113 Cash 17 1.0 5.2 +413% @ Sales down 12% to NZ$1.13m, COVID-19 delays in all regions @ Total r
Slide 7: Revenue FY20 vs FY21
For personal use only 3000000 FY20 FY21 2500000 ⚫ 2000000 ⚫ 1500000 ⚫ 1000000 500000 0 Total Device SUS R&D Revenue Revenue Revenue
Slide 8: China Market Update
China Market Update TruScreen's most established market with a growing sales trend. China is the focus of TruScreen’s commercial strategy CHINA FY2021 Market Progress: * +65% commercial users * Increase published clinical data * COGA trial progress * 78% of FY21 Sales Pipeline to be driven by”: * Lo
Slide 9: For personal use only
For personal use only • • • • • • • • • • • •
Slide 10: For personal use only
For personal use only ► ► ► ► ► ► ► ► ► 10
Slide 11: For personal use only
e Si", Sy or. 8 Ee age re) truscreen
Slide 12: Our path for growth
Our path for growth” sssetting the foundations 2014-2020 For personal use on Listed on NZAX Gen 2 developed Grow markets Expansion of distribution network Product registrations Early market access Clinical Evaluations Commenced COGA Evaluation Completed RHW Trial (AU) Increase published evidence WHO
Slide 13: For personal use only
For personal use only 13 ► ► ► ► ► ► ► ► ► ► ► ► ► ► ► ► ► ► ► ►
Slide 14: For personal use only
For personal use only ⚫ ⚫ ⚫ ⚫ ⚫ ● ● ● ● 14
Slide 15: For personal use only
For personal use only 15
Slide 16: Contacts
16 Juliet Hull Guy Robertson Chief Executive Officer Chief Financial Officer M — +64 27 249 3060 M — +61 407 983 270 E — juliethull@truscreen.com E - guyrobertson@truscreen.com
Slide 17: References
7 References 1. TruScreen Ultra, Instructions for Use. One day training required and no need for medical or nursing degree or training. WHO, HPV and, Cervical Cancer Fact sheet, 1 November 2020, SURE, {/ st a /news- . WHO guideline for screening and treatment of cervical pre-cancer lesions for cervi
Slide 18: Disclaimers
18 Disclaimers truscreen This presentation has been prepared by TruScreen Group Limited (the "Company’) and is dated 06 September 2021. This presentation contains summary information about the Company and its activities which is current as at the date of this presentation. The information in this pr
TruScreen Group — Shareholder Meeting (September 2021) on 6ix